Involving patients, relatives and healthcare professionals in prioritising research into tumours of the brain and spinal cord!
The Neuro-Oncology Group Priority Setting Partnership is asking all patients, carers, relatives and healthcare professionals to send us any unanswered questions they have about the treatment and care of patients with a tumour of the brain or spinal cord.
Question(s) can be submitted online athttp://www.neuro-oncology.org.uk/
We are delighted to announce that the Mexican Branch of the Iberoamerican Cochrane Centre has been registered by the Monitoring and Registration Committee (MaRC). This new Branch, co-directed by Dr.
Giordano Pérez-Gaxiola and Dr. Alejandro González Garay will continue promoting Cochrane throughout Mexico.
Instituto Nacional de Pediatría (Torre de Investigación)
Av. Insurgentes Sur No. 3700 Letra C,
Col. Insurgentes Cuicuilco,
Del. Coyoacan C.P.
04530, México, D.F.
The Australasian Cochrane Centre is delighted to announce the establishment of the Japanese Cochrane Branch, effective February 2014. The main base of the branch will be at the National Center for Child Health and Development (NCCHD) in Tokyo, which also hosts the Japanese Satellite of the Cochrane Pregnancy and Childbirth Group.
Post: Translation Co-ordinator
Specifications: Full time, permanent
Salary: Up to £42,000 dependent on skills and experience
Application closing date: 20 March 2014
Cochrane is an independent, international network of over 31,000 health practitioners, researchers and patient advocates, responding to the challenge of making the evidence generated through research more useful for informing decisions about health.Contributor's Information Contributor's name: Rachael Wallwork Email address: firstname.lastname@example.org
26 February 2014External link for more information: http://doi.wiley.com/10.1002/14651858.CD003440.pub3 Contributor's Information Contributor's name: Cochrane CEAD Email address: email@example.com
A recent article in the Policy Forum of PLoS Medicine explores the concept of 'living systematic reviews' - "high quality, up-to-date online summaries of health research that are updated as new research becomes available" - as a new approach to evidence synthesis.The article's authors are all Cochrane contributors.External link for more information: http://www.plosmedicine.org/article/info%3Adoi%2F10.137...
The Call for Applications for the 2014 edition of the Reviews for Africa Programme Nigeria, which was earlier announced, has been extended.
For full details on eligibility criteria, mode of application etc and to fill the application form please visit:
New deadline for applications:
16:00 hrs 16 February 2014
Emmanuel at firstname.lastname@example.org
Bisi at email@example.comExternal link for more information: http://nigeria.cochrane.org/reviews-africa-programme-ra...
11 February 2014
New Wikiproject Medicine partnership boosts content
100 free accounts to The Cochrane Library for Wikipedia editors
The ALOIS Community has been included in the European Patients Academy catalogue of models of successful and sustainable patient partnerships.
The European Patients' Academy of Therapeutic Innovation has been established to "provide scientifically reliable, objective, comprehensive information to patients on the research and development process of medicines." In 2013 the Academy prepared a catalogue and a report on successful public private partnerships (PPPs) between patients’ organizations, industry, and academia.External link for more information: http://www.patientsacademy.eu/index.php/en/news/262-sus... Contributor's Information Contributor's name: Cochrane CEAD Email address: firstname.lastname@example.org
Antipsychotic drugs are the main treatment for schizophrenia, and are grouped into older drugs (first generation or ‘typical’) and newer drugs (second generation or ‘atypical’). However, antipsychotic drugs also have serious side effects, particularly movement disorders such as uncontrollable shaking, tremors, muscle stiffness, tiredness, weight gain and the inability to sit still.
Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia.
A search for trials was carried out in July 2012. The review now includes seven studies with a total of 479 participants and assesses the effects of perazine for people with schizophrenia. Comparisons of perazine versus placebo (‘dummy’ treatment) and versus other antipsychotic drugs revealed no clear differences or superiority of perazine. However, only a handful of studies have been undertaken and the number of participants in each study was small. In addition the studies avialable were of limited quality with data for the main outcomes of interest rated as low or very low quality. As perazine is a cheap drug and there is some limited evidence that it may cause less side effects than other older antipsychotic drugs, further large scale, well designed and well-reported studies are much needed.
Physical health care monitoring can take a variety of forms from simple checks carried out by the person themselves to complex specific health checks carried out by health professionals. Monitoring helps identify current health problems and also anticipate future health problems.
In August 2006 the United Kingdom’s Department of Health issued guidance on how to provide better care for the physical health needs of people with serious mental illness. Spearhead Trusts, the Royal College of Psychiatrists, the National Institute for Clinical Excellence and other organisations all promoted the use of physical health care monitoring for people with mental health problems.
This review intended to find evidence to support this guidance. The authors’ conclude that current guidance and practice on physical health monitoring lacks a firm basis in research and there is little evidence to support this growing trend. They based their conclusions on results from a search carried out for trials in 2012 which found no relevant randomised studies. Current monitoring is mainly based on the agreement of experts, medical experience and good intentions. This does not mean that physical health monitoring is invalid, wrong or not of benefit to the physical health of people with severe mental illness, only that there is as yet no definite proof. Physical health care monitoring has the potential and promise to improve quality of life and help people with mental health problems live longer, but at this stage the information is uncertain and the research evidence unclear.
Dear Cochrane colleagues,
We would like to ask for 10 minutes of your time to answer a short survey (6 questions) about the interpretation of different grades of quality of evidence.
GRADE has become an important tool for systematic reviews to convey the confidence in effect estimates. A concern, however, is that producers and end-users of systematic reviews give different meanings to the terms “high”, “moderate”, “low”, and “very low” regarding the quality of the evidence, which may lead to different interpretations of the same information.
The Cochrane Collaboration Steering Group is pleased to announce that the 2016 Cochrane Colloquium will be held in Seoul, South Korea.
The event will be organized and hosted by the Korean Branch of the Australasian Cochrane Centre and will be the third Colloquium in Asia after Singapore in 2009 and Hyderabad in 2014, and the first one in East Asia. This affirms Cochrane’s ambition and willingness to enhance capacity in this part of the world and address local and regional issues.
The Lancet has published an open-access series addressing the topics of value and waste in biomedical research, with its list of authors including many Cochrane contributors.The LancetResearch: increasing value, reducing waste
Published January 8, 2014
Executive summaryExternal link for more information: http://www.thelancet.com/series/research
Consumer Stipends Open for the Cochrane Canada Symposium 2014
We offer stipends to help cover expenses, up to the amount of each allotted subsidy awarded, to attend our Symposium. While we recognize we are all consumers of healthcare services, we offer financial support for the attendance of:External link for more information: https://www.eventsforce.net/cochrane/frontend/reg/tOthe...